{"entity":{"id":"brainchild-bio","kind":"company","name":"BrainChild Bio","aka":[],"tldr":"BrainChild Bio develops CAR-T cell therapies for brain tumours, starting with children. Its lead treatment, for diffuse intrinsic pontine glioma, a brainstem tumour of childhood, entered a phase 2 trial in 2026 intended to support an application for approval.","summary":"BrainChild Bio, with offices in Seattle and Cambridge, Massachusetts, is a clinical-stage company developing CAR-T therapies for tumours of the central nervous system, built on technology developed at Seattle Children's and exclusively licensed to the company in December 2023. On 8 September 2026 it announced a USD 116 million Series A led by an undisclosed private family fund and foundation, with Seattle Children's, its initial investor, and WRF Capital.\n\nMost of the money goes to ILLUMINATE (NCT07680439), a pivotal phase 2 trial of BCB-276, an autologous B7-H3-targeted CAR-T for diffuse intrinsic pontine glioma (DIPG), designed to support a future Biologics License Application to the FDA. The financing also supports BCB-214, a triple-targeting CAR-T being advanced to initial clinical testing in glioblastoma, and further paediatric and adult brain tumour programmes, including brain metastases.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.brainchildbio.com/"},{"label":"Series A press release, September 2026","url":"https://www.biospace.com/press-releases/brainchild-bio-closes-116-million-series-a-financing"},{"label":"ClinicalTrials.gov: NCT07680439","url":"https://clinicaltrials.gov/study/NCT07680439"}],"tags":[],"related":[],"cancers":["dipg-dmg","glioblastoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","glioma-car-t"],"targets":["b7h3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07680439"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated in the release; the licence from Seattle Children's dates from December 2023. Earlier support from Seattle Children's is described only as its initial investment, with no amount."],"hq":"Seattle, WA","country":"US","companyType":"cell-therapy","website":"https://www.brainchildbio.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"amountUsd":116000000,"source":"https://www.biospace.com/press-releases/brainchild-bio-closes-116-million-series-a-financing","note":"Led by an undisclosed private family fund and foundation, with Seattle Children's (the initial investor) and WRF Capital"}]},"route":"/companies/brainchild-bio/","neighbours":{"cancer":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"}],"trial":[{"id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/"}]}}